ライフサイエンスコーパス: adjuvant chemotherapy

1 4 to < 30 v >/= 30 kg/m(2); prior v no prior adjuvant chemotherapy).

2 relapsed within 12 months of neoadjuvant or adjuvant chemotherapy.

3 on the basis of MammaPrint may safely avoid adjuvant chemotherapy.

4 with stage III colon carcinomas treated with adjuvant chemotherapy.

5 nephrectomy, patients were followed without adjuvant chemotherapy.

6 ublication, type and quality of studies, and adjuvant chemotherapy.

7 Gy in 1 week, early surgery and 6 courses of adjuvant chemotherapy.

8 enous resection (VR = 28%), and 70% received adjuvant chemotherapy.

9 may be promising direction for the field of adjuvant chemotherapy.

10 e complete excision, and were due to receive adjuvant chemotherapy.

11 ependent cohorts received fluorouracil-based adjuvant chemotherapy.

12 ve and may be recommended as neoadjuvant and adjuvant chemotherapy.

13 either no trastuzumab or trastuzumab, after adjuvant chemotherapy.

14 ations are required to determine the role of adjuvant chemotherapy.

15 ain survival benefit from fluorouracil-based adjuvant chemotherapy.

16 therapy or to immediate surgery, followed by adjuvant chemotherapy.

17 i-Ang2 antibody) as an add-on to neoadjuvant/adjuvant chemotherapy.

18 more days from surgery to the first dose of adjuvant chemotherapy.

19 al survival benefits from fluorouracil-based adjuvant chemotherapy.

20 005, and December 31, 2010, and treated with adjuvant chemotherapy.

21 inant Ang1 variant) improved the efficacy of adjuvant chemotherapy.

22 One treatment strategy after orchiectomy is adjuvant chemotherapy.

23 ion, orbital external-beam radiotherapy, and adjuvant chemotherapy.

24 val after treatment with anthracycline-based adjuvant chemotherapy.

25 tients with stage II CRC who did not receive adjuvant chemotherapy.

26 hological criteria in selecting patients for adjuvant chemotherapy.

27 consent prior to starting the first cycle of adjuvant chemotherapy.

28 urgical cytoreduction and neoadjuvant versus adjuvant chemotherapy.

29 adenocarcinomas sampled before and after neo-adjuvant chemotherapy.

30 , 363 received preoperative and 328 received adjuvant chemotherapy.

31 mes is unknown, as is the role of dose-dense adjuvant chemotherapy.

32 fter completion of 4 to 6 months of systemic adjuvant chemotherapy.

33 <.001) had decreased likelihood of receiving adjuvant chemotherapy.

34 ccording to whether or not patients received adjuvant chemotherapy.

35 e separately the benefit of concomitant plus adjuvant chemotherapy.

36 oncologist areas were less likely to receive adjuvant chemotherapy.

37 the association between race and receipt of adjuvant chemotherapy.

38 e for patients with breast cancer undergoing adjuvant chemotherapy.

39 st cancers to help guide recommendations for adjuvant chemotherapy.

40 ings to reduce physician recommendations for adjuvant chemotherapy.

41 ced against the absolute survival benefit of adjuvant chemotherapy.

42 e OS in patients with resected PAC receiving adjuvant chemotherapy.

43 on and/or surgery was performed, followed by adjuvant chemotherapy.

44 Four patients (33.3%) received adjuvant chemotherapy.

45 significant predictor in patients undergoing adjuvant chemotherapy.

46 ression regimen or secondary prevention with adjuvant chemotherapy.

47 f jaundice and to potentially facilitate neo-adjuvant chemotherapy.

48 ases have similarly improved prognosis after adjuvant chemotherapy.

49 ancer were N-stage, perineural invasion, and adjuvant chemotherapy.

50 survival in patients with colon cancer with adjuvant chemotherapy.

51 cancer patients treated with trastuzumab and adjuvant chemotherapy.

52 stage III colon cancer patients treated with adjuvant chemotherapy.

53 nosis could be maintained with two cycles of adjuvant chemotherapy.

54 t tissues despite systemic administration of adjuvant chemotherapy.

55 ber of lymph nodes harvested, and receipt of adjuvant chemotherapy.

56 vasion show no recurrence and may warrant no adjuvant chemotherapy.

57 e effective when followed by enucleation and adjuvant chemotherapy.

58 eing intensively investigated as primary and adjuvant chemotherapies.

59 (HR 0.65, 0.56-0.76) and concomitant without adjuvant chemotherapy (0.80, 0.70-0.93) but not adjuvant

60 Among the 179 patients who received adjuvant chemotherapy, 108 patients (60%) received oxali

61 ph node positivity ratio (0%: 4.6; 3.4-6.4), adjuvant chemotherapy (2.4; 2.0-3.0), pathologic T stage

62 After cycle 1 of adjuvant chemotherapy, 596 patient questionnaires were c

63 s are associated with delaying initiation of adjuvant chemotherapy 91 or more days.

64 To determine whether adjuvant chemotherapy (AC) after neoadjuvant chemoradiat

65 re is limited evidence to support the use of adjuvant chemotherapy (AC) after radical nephroureterect

66 endorses evaluating >/=12 lymph nodes (LNs), adjuvant chemotherapy (AC) for stage III patients, and A

67 Effectiveness of adjuvant chemotherapy according to time to initiation af

68 In addition, protective effect conferred by adjuvant chemotherapy (ACT) on GC was observed in patien

69 Information regarding NAC, adjuvant chemotherapy (aCT), breast conserving surgery (

70 its predictive value regarding survival from adjuvant chemotherapy (ACT).

71 Adjuvant chemotherapy administered at different time poi

72 e margin, abdominoperineal resection, and no adjuvant chemotherapy administration were independently

73 s of metastatic progression and suggest that adjuvant chemotherapy affords a survival benefit by dire

74 She presented for adjuvant chemotherapy after an optimal (R0) resection.

75 Further studies on the specific benefits of adjuvant chemotherapy after concomitant chemoradiotherap

76 This study suggests that adjuvant chemotherapy after curative resection of stage

77 d, phase 3 trials comparing observation with adjuvant chemotherapy after preoperative (chemo)radiothe

78 g by the odds (ATT analysis) and adjustment, adjuvant chemotherapy after resection of a stage II OCC

79 d June 2013, 180 HNSCC patients eligible for adjuvant chemotherapy after surgery with curative intent

80 uvant chemotherapy (0.80, 0.70-0.93) but not adjuvant chemotherapy alone (0.87, 0.68-1.12) or inducti

81 tcomes than those who undergo resection with adjuvant chemotherapy alone or chemotherapy with cranial

82 ional OS advantage beyond that achieved with adjuvant chemotherapy alone.

83 Receipt of adjuvant chemotherapy among both white and black patient

84 Among these patients, 179 (35.5%) had adjuvant chemotherapy and 325 (64.5%) had no adjuvant tr

85 The association between adjuvant chemotherapy and improved survival was consiste

86 S receipt was associated with reduced use of adjuvant chemotherapy and lower health care spending amo

87 cognitive impairment (CRCI) is common during adjuvant chemotherapy and may persist.

88 Patients underwent subsequent surgery with adjuvant chemotherapy and radiation therapy.

89 ) trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy (CTRT) versus rad

90 trogen receptor-positive tumors and received adjuvant chemotherapy and radiotherapy for their primary

91 The role of routine adjuvant chemotherapy and radiotherapy is not clearly es

92 3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy versus pelvic rad

93 t survival of patients with high sTILs after adjuvant chemotherapy and supports the integration of sT

94 he association between time to initiation of adjuvant chemotherapy and survival was evaluated using C

95 been shown to prohibit the administration of adjuvant chemotherapy and survival.

96 erall survival between patients who received adjuvant chemotherapy and those who underwent observatio

97 at sufficient risk for recurrence to warrant adjuvant chemotherapy and who remained premenopausal, th

98 ed by immune checkpoint blockade, negated by adjuvant chemotherapy, and dependent on inhibition of th

99 k histopathologic features were treated with adjuvant chemotherapy, and no metastases were recorded i

100 entified lymph node ratio, administration of adjuvant chemotherapy, and pathologic T stage as being t

101 e status (0 vs 1-2), previous neoadjuvant or adjuvant chemotherapy, and presence of brain metastases

102 ision combined with radiotherapy and/or (neo)adjuvant chemotherapy as appropriate, and in the palliat

103 , with black patients less likely to receive adjuvant chemotherapy as compared with white patients (r

104 of concomitant chemotherapy with and without adjuvant chemotherapy as distinct groups.

105 emcitabine to anthracycline and taxane-based adjuvant chemotherapy at this dose and schedule confers

106 of stage II patients that might benefit from adjuvant chemotherapy based on lack of CDX2 expression i

107 to demonstrate the feasibility of customized adjuvant chemotherapy based on timely biomarker analysis

108 Validated predictive markers of adjuvant chemotherapy benefit for stage II or III colon

109 ntified in major complications or receipt of adjuvant chemotherapy between robotic and open pancreate

110 To investigate receipt of adjuvant chemotherapy by age category (18-49, 50-64, and

111 Neo-adjuvant chemotherapy can rapidly and profoundly affect

112 ge oestrogen receptor-negative breast cancer adjuvant chemotherapy cohort (Nottingham-oestrogen recep

113 025, p(interaction)=0.126) when treated with adjuvant chemotherapy compared with patients undergoing

114 he effect of surgical approach on receipt of adjuvant chemotherapy, complications, and overall surviv

115 women with breast cancer receiving standard adjuvant chemotherapy conducted at 11 outpatient oncolog

116 to conventional prognostic factors to guide adjuvant chemotherapy (CT) decisions.

117 mpared overall survival after neoadjuvant or adjuvant chemotherapy (CT), radiotherapy (RT), or combin

118 is a tumor gene-profiling test that aids in adjuvant chemotherapy decision-making.

119 at miR-1269a is a potential marker to inform adjuvant chemotherapy decisions for CRC patients and a p

120 rofiling assays are frequently used to guide adjuvant chemotherapy decisions in hormone receptor-posi

121 For black patients, receipt of adjuvant chemotherapy did not differ across insurance ca

122 INTERPRETATION: Addition of bevacizumab to adjuvant chemotherapy did not improve overall survival f

123 se-dense chemotherapy compared with standard adjuvant chemotherapy did not result in a statistically

124 Overall, adjuvant chemotherapy did not significantly improve dise

125 The addition of radiation to adjuvant chemotherapy did not significantly improve over

126 patients treated with upfront resection and adjuvant chemotherapy (DM 83.0%, LR 16.9%) regardless of

127 erine is a promising candidate in anticancer adjuvant chemotherapy, due to its distinct pharmacologic

128 herapies, and early tumor resection and (neo)adjuvant chemotherapy fails to improve a poor prognosis.

129 atures (nodal or margin involvement or LVI), adjuvant chemotherapy followed by radiation provides a b

130 h resected biliary tract cancer when used as adjuvant chemotherapy following surgery and could be con

131 Ang2/Ang1, anti-Tie2) to improve neoadjuvant/adjuvant chemotherapies for TNBC.

132 Given that randomized trials exploring adjuvant chemotherapy for bladder cancer have been under

133 patients were randomized to receive standard adjuvant chemotherapy for breast cancer with either plac

134 the CTCAE system is high in women undergoing adjuvant chemotherapy for breast cancer.

135 rapy completion rates in patients undergoing adjuvant chemotherapy for breast cancer.

136 cologists and travel distance and receipt of adjuvant chemotherapy for colon cancer within 90 days of

137 recommended to assess benefits and risks of adjuvant chemotherapy for each patient.

138 Adjuvant chemotherapy for early breast cancer has improv

139 added to anthracycline and taxane-containing adjuvant chemotherapy for early breast cancer.

140 sphamide, methotrexate, and fluorouracil) as adjuvant chemotherapy for early breast cancer.

141 ong women undergoing non-anthracycline-based adjuvant chemotherapy for early-stage breast cancer, the

142 ablished with the addition of trastuzumab to adjuvant chemotherapy for human epidermal growth factor

143 etect-high patients having better outcome on adjuvant chemotherapy for invasive disease-free survival

144 The role of adjuvant chemotherapy for patients with rectal cancer af

145 d population studies, the precise benefit of adjuvant chemotherapy for patients with rectal cancer fo

146 tly support the routine use of postoperative adjuvant chemotherapy for patients with rectal cancer tr

147 n-inferiority of 3 months versus 6 months of adjuvant chemotherapy for patients with stage III colon

148 n-inferiority of 3 months versus 6 months of adjuvant chemotherapy for patients with stage III colon

149 rnational consensus exists on the benefit of adjuvant chemotherapy for patients with UTUCs after neph

150 Adjuvant chemotherapy for resected early-stage non-small

151 ation at diagnosis and may avoid unnecessary adjuvant chemotherapy for those who are not at risk for

152 ve therapeutic potential in conjunction with adjuvant chemotherapy for TNBC.

153 very 3-4 weeks, starting with neoadjuvant or adjuvant chemotherapy, for about 6 months and then every

154 ed (1:1) by minimisation to either immediate adjuvant chemotherapy (four cycles of gemcitabine plus c

155 2 NSCLC who underwent complete resection and adjuvant chemotherapy from 2006 to 2010 were identified

156 A3-positive NSCLC who did or did not receive adjuvant chemotherapy from 443 centres in 34 countries (

157 ishing the more aggressive ER+ BCa requiring adjuvant chemotherapy from the less aggressive cancers b

158 The patient received adjuvant chemotherapy (Gemcitabine) but expired 10 month

159 certainty about whether the effectiveness of adjuvant chemotherapy generalises to these groups, hinde

160 atient-reported toxicities, this schedule of adjuvant chemotherapy given during and after radiotherap

161 Those receiving adjuvant chemotherapy had modestly higher doses ( P = .0

162 Since the 1990s, fluorouracil-based adjuvant chemotherapy has significantly reduced the risk

163 he only chance for cure, and advancements in adjuvant chemotherapy have improved long-term outcomes i

164 ox modeling demonstrated that treatment with adjuvant chemotherapy (hazard ratio [HR], 0.78; 95% CI,

165 ated an improvement in overall survival with adjuvant chemotherapy (hazard ratio, 0.70; 95% CI, 0.64

166 icant (p=0.01) in favour of concomitant plus adjuvant chemotherapy (HR 0.65, 0.56-0.76) and concomita

167 neural invasion (HR = 1.50 [1.01-2.23]), and adjuvant chemotherapy (HR = 0.69 [0.48-0.97]) were indep

168 f the primary tumor (HR: 2.07 P = 0.027) and adjuvant chemotherapy (HR: 1.95, P = 0.009) were associa

169 nefit (median survivals: 24.8 vs 21.0 mo for adjuvant chemotherapy; HR = 0.81; 95% CI: 0.77-0.86; P <

170 tures (median survivals: 54.6 vs 42.7 mo for adjuvant chemotherapy; HR=0.90; 95% CI: 0.75-1.08; P = 0

171 the six International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration randomized co

172 abine-based chemoradiation and postoperative adjuvant chemotherapy impairs tolerability and feasibili

173 Adjuvant chemotherapy improves outcomes of patients with

174 Receipt of adjuvant chemotherapy improves survival after resected P

175 Perioperative or adjuvant chemotherapy improves survival in patients with

176 We aimed to establish whether adjuvant chemotherapy improves the outcome of such patie

177 ve: To determine whether tailored dose-dense adjuvant chemotherapy improves the outcomes of early bre

178 Since the introduction of adjuvant chemotherapy in 2004, no substantial progress h

179 , gemcitabine has not been added to standard adjuvant chemotherapy in breast cancer for any subgroup.

180 y mortality after surgery and treatment with adjuvant chemotherapy in colon cancer are poorly underst

181 Adjuvant chemotherapy in early stage breast cancer has b

182 d to evaluate the addition of bevacizumab to adjuvant chemotherapy in early-stage resected NSCLC.

183 nical-pathological and genomic risk to guide adjuvant chemotherapy in node-negative breast cancer and

184 that evaluated the benefit of platinum-based adjuvant chemotherapy in non-small-cell lung cancer were

185 The use of adjuvant chemotherapy in patients with breast cancer may

186 ese data lend further support for the use of adjuvant chemotherapy in patients with locally advanced

187 iveness of cystectomy versus cystectomy plus adjuvant chemotherapy in real-world patients.

188 The relative effectiveness of adjuvant chemotherapy in reducing mortality in patients

189 The need for adjuvant chemotherapy in stage II colon cancer is still

190 rative therapy should be offered 6 months of adjuvant chemotherapy in the absence of contraindication

191 rative therapy should be offered 6 months of adjuvant chemotherapy in the absence of medical or surgi

192 rative therapy should be offered 6 months of adjuvant chemotherapy in the absence of medical or surgi

193 s) who had completed three or more cycles of adjuvant chemotherapy in the previous 6 to 60 months and

194 to consider when making a recommendation for adjuvant chemotherapy, including tumor size, histopathol

195 PAG5 protein expression, anthracycline-based adjuvant chemotherapy increased breast cancer-specific s

196 The OS benefit of oxaliplatin-based adjuvant chemotherapy, increasing over time and with the

197 itative clinical stage/tumor volume staging, adjuvant chemotherapy, intraoperative heated chemo, fema

198 with stage I disease have a recurrence, and adjuvant chemotherapy is .

199 have pN2 disease have improved outcomes when adjuvant chemotherapy is administered before, rather tha

200 Determine whether adjuvant chemotherapy is associated with a survival bene

201 Randomized trials have demonstrated that adjuvant chemotherapy is associated with improved long-t

202 fluorouracil, and oxaliplatin (FOLFOX)-based adjuvant chemotherapy is controversial, possibly owing t

203 assurance to patients and clinicians in whom adjuvant chemotherapy is indicated to reduce recurrence

204 More effective systemic adjuvant chemotherapy is necessary to improve the outcom

205 is highly prognostic and determines whether adjuvant chemotherapy is needed if residual tumor is fou

206 Adjuvant chemotherapy is not recommended for patients wi

207 not statistically associated with receipt of adjuvant chemotherapy (low v high density: OR, 0.98; P=.

208 In 59 patients receiving adjuvant chemotherapy, low CHD5 expression was associate

209 However, adjuvant chemotherapy might benefit patients with a tumo

210 s with N2 NSCLC after complete resection and adjuvant chemotherapy, modern PORT seems to confer an ad

211 igned patients who were scheduled to undergo adjuvant chemotherapy (N = 230) to Onco-Move, OnTrack, o

212 6% improvement in overall survival with Neo-Adjuvant Chemotherapy (NAC), many do not respond.

213 Adjuvant chemotherapy offers a survival benefit to a num

214 e (T1, T2, or T3 and N1), either 6 months of adjuvant chemotherapy or a shorter duration of 3 months

215 Adjuvant chemotherapy or radiotherapy did not appear to

216 CES signature forecasts patient response to adjuvant chemotherapy or radiotherapy.

217 herapy followed by surgery and the remaining adjuvant chemotherapy or to immediate surgery, followed

218 Adjuvant chemotherapy (OR 0.28) and chemoradiotherapy (O

219 y of oncologists were less likely to receive adjuvant chemotherapy (OR, 0.85; P=.03).

220 node dissection ( P = .0464), and receipt of adjuvant chemotherapy ( P = .0161) were significantly as

221 er were randomly assigned to either standard adjuvant chemotherapy (physician's choice of either cycl

222 ther pertuzumab or placebo added to standard adjuvant chemotherapy plus 1 year of treatment with tras

223 st cancer, who had completed neoadjuvant and adjuvant chemotherapy plus trastuzumab with no evidence

224 y cardiac toxicity is a risk associated with adjuvant chemotherapy plus trastuzumab.

225 n typically receive a total of 4-6 cycles of adjuvant chemotherapy post-surgery, with the combination

226 s met study inclusion criteria; 23% received adjuvant chemotherapy postcystectomy.

227 ur multidisciplinary tumor board recommended adjuvant chemotherapy, postmastectomy radiation therapy,

228 ur multidisciplinary tumor board recommended adjuvant chemotherapy, postsurgical radiation therapy, a

229 Fluorouracil plus leucovorin (FU + LV) adjuvant chemotherapy reduced the risk of recurrence and

230 ted with a decreased likelihood of receiving adjuvant chemotherapy, regardless of insurance status.

231 es, supporting the need for a more intensive adjuvant chemotherapy regimen for this subgroup.

232 meta-analysis to identify the most effective adjuvant chemotherapy regimen.

233 Different adjuvant chemotherapy regimens are available for early-s

234 ntario guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer a

235 (CCO) guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer i

236 Decisions regarding adjuvant chemotherapy regimens should take into account

237 Adherence to reporting adjuvant chemotherapy-related adverse effects using the

238 In the National Cancer Database, adjuvant chemotherapy remained efficacious when started

239 postoperative plasma, we observe evidence of adjuvant chemotherapy resistance and identify patients w

240 at a high risk of recurrence (T4 and/or N2), adjuvant chemotherapy should be offered for a duration o

241 s who would ordinarily be advised to receive adjuvant chemotherapy should receive ovarian suppression

242 stage II CRC who received fluorouracil-based adjuvant chemotherapy showed a substantial gain in survi

243 ts who underwent tumor resection and started adjuvant chemotherapy showed improved survival with preo

244 Standard adjuvant chemotherapy showed significant improvements in

245 Adjuvant chemotherapy significantly improved disease-fre

246 For patients receiving adjuvant chemotherapy, solid-predominant adenocarcinoma

247 ancer surgery may still benefit from delayed adjuvant chemotherapy started up to 4 months after surge

248 With the advent of modern adjuvant chemotherapy strategies, postoperative radiothe

249 hen at least half of the population received adjuvant chemotherapy, the cost increased to $30.2 milli

250 stratified according to nodal status, prior adjuvant chemotherapy, the interval from the last dose o

251 6 days after the first day of last course of adjuvant chemotherapy to CM maintenance (cyclophosphamid

252 apy before scheduled enucleation followed by adjuvant chemotherapy to complete six cycles, regardless

253 Administering adjuvant chemotherapy to stage II colon cancer patients

254 expression in combination may identify which adjuvant chemotherapy-treated TNBC patients have a highe

255 spectively from patients participating in an adjuvant chemotherapy trial (NCCTG N0147).

256 First-generation adjuvant chemotherapy trials reported a 0.27% 8-year cum

257 cing adoption of the assay and its impact on adjuvant chemotherapy use in clinical practice remain im

258 The associations between complications and adjuvant chemotherapy use or treatment delay (>/= 70 day

259 nical features offers the potential to guide adjuvant chemotherapy use with greater precision.

260 and under scenarios that reflected different adjuvant chemotherapy use.

261 follow-up, RFS remains superior for standard adjuvant chemotherapy versus capecitabine, especially in

262 P53/EGFR comutations in randomized trials of adjuvant chemotherapy versus observation.

263 rior chamber invasion received six cycles of adjuvant chemotherapy (vincristine, carboplatin, and eto

264 wo-year EFS for patients with HRFs requiring adjuvant chemotherapy was 0.96 (95% CI, 0.89 to 0.98), a

265 ed by cystectomy, and cystectomy followed by adjuvant chemotherapy was 14% (95% CI, 11% to 17%), 19%

266 persistent opioid use in patients receiving adjuvant chemotherapy was 15% to 21%, compared with 7% t

267 Adjuvant chemotherapy was also associated with a signifi

268 In this observational study, adjuvant chemotherapy was associated with improved survi

269 ancer cohort, MN risk after radiation and/or adjuvant chemotherapy was low but higher than previously

270 without high risk features by NCCN criteria, adjuvant chemotherapy was not independently associated w

271 at sufficient risk for recurrence such that adjuvant chemotherapy was warranted.

272 ular invasion, negative surgical margin, and adjuvant chemotherapy were also associated with better c

273 stage II CRC who had clinical follow-up and adjuvant chemotherapy were analyzed.

274 on which to base the decision to administer adjuvant chemotherapy were compared: the 70-gene signatu

275 ion, T-stage, N-stage, resection margin, and adjuvant chemotherapy were correlated with OS and DFS.

276 rgins, lymph nodes harvested, and receipt of adjuvant chemotherapy were equivalent between groups.

277 Postoperative complications and time to adjuvant chemotherapy were similar.

278 ority in order to optimize the advantages of adjuvant chemotherapy while avoiding unnecessary toxicit

279 pling risk-adapted intensive neoadjuvant and adjuvant chemotherapies with surgery and/or radiotherapy

280 ormed to determine the potential benefits of adjuvant chemotherapy with and without prophylactic cran

281 igh-risk stage II or stage III colon cancer, adjuvant chemotherapy with fluoropyrimidine monotherapy

282 The patient underwent adjuvant chemotherapy with gemcitabine for 6 months and

283 the only potentially curative treatment, and adjuvant chemotherapy with gemcitabine or S-1, an oral f

284 alysis of individual patient data to compare adjuvant chemotherapy with observation for patients with

285 istant metastases, who underwent surgery and adjuvant chemotherapy with or without postoperative radi

286 without adjuvant therapy and 90 who received adjuvant chemotherapy with or without radiation (22%).

287 Compared with surgery alone, adjuvant chemotherapy with or without radiation was asso

288 both unadjusted and multivariable analysis, adjuvant chemotherapy with or without radiation was not

289 In this analysis, adjuvant chemotherapy with or without radiation was not

290 Patients were stratified by receipt of adjuvant chemotherapy with or without radiation.

291 ib 150 mg per day for 2 years after standard adjuvant chemotherapy with or without radiotherapy.

292 stage III colon cancer who are being offered adjuvant chemotherapy with oxaliplatin and a fluoropyrim

293 represented at the tumor board meeting, and adjuvant chemotherapy with oxaliplatin and capecitabine

294 are noninferior to primary cytoreduction and adjuvant chemotherapy with respect to overall and progre

295 ge II obstructing colon cancer (OCC) who had adjuvant chemotherapy with those who did not.

296 have been no studies evaluating the role of adjuvant chemotherapy, with or without prophylactic cran

297 patients in the study cohort, 75.7% received adjuvant chemotherapy within 90 days of colectomy.

298 crine therapy alone versus those who require adjuvant chemotherapy would be impactful for improving p

299 01) and this was independent of stage, race, adjuvant chemotherapy, year of study, number of particip

300 ry may delay a patient's ability to tolerate adjuvant chemotherapy, yet the urgency of chemotherapy i